ArticleAIDS (London, England)2018

Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.

Paul G Rubinstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.